How much should investors expect sales of Keytruda, the best-selling drug in the world, to decline in the coming years? And can they trust Merck’s guidance on that decline? The problems with ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. The Keytruda-Lenvima regimen ...

Deutsche Bank analyst James Shin downgraded Merck (MRK) to Hold from Buy with a price target of $105, down from $128. The firm believes the ...

There remains uncertainty about how much longer Keytruda can help patients live, as the data is still not mature. MSD says the drug could give second line patients as much as 11 months ...

Pembrolizumab (Keytruda, Merck Sharp & Dohme) is indicated for 'the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and ...

Also Read: RJK Jr.’s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing At an interim analysis, the Keytruda plus Lenvima-based regimen demonstrated a statistically significant ...

Merck blamed the lower than expected forecast on the decision to pause shipments of its Gardasil vaccine to China until at least mid-year. Gardasil is given to patients to prevent human papillomavirus ...

PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...

Analyst at TD Cowen said Merck (NSE:PROR)'s valuation would likely bottom out in 2026, two years before Keytruda's U.S. patent expires in 2028. "The story other than Keytruda has not improved ...

Merck’s top-line growth in the fourth quarter is likely to have been driven by cancer drug Keytruda, like in the previous quarters, backed by additional indications and patient demand.